Omeros Corporation $OMER Shares Acquired by Bank of America Corp DE

Bank of America Corp DE boosted its stake in shares of Omeros Corporation (NASDAQ:OMER - Free Report) by 57.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 204,805 shares of the biopharmaceutical company's stock after acquiring an additional 74,997 shares during the quarter. Bank of America Corp DE owned about 0.28% of Omeros worth $2,163,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Assetmark Inc. purchased a new position in Omeros during the 1st quarter valued at about $38,000. International Assets Investment Management LLC increased its stake in Omeros by 16.0% in the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 800 shares during the last quarter. Leonteq Securities AG purchased a new position in Omeros during the first quarter worth about $106,000. Caitong International Asset Management Co. Ltd acquired a new stake in Omeros in the 4th quarter worth about $159,000. Finally, Avantax Planning Partners Inc. grew its holdings in Omeros by 59.8% in the 1st quarter. Avantax Planning Partners Inc. now owns 21,100 shares of the biopharmaceutical company's stock valued at $223,000 after buying an additional 7,900 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Insider Buying and Selling

In other Omeros news, Director Arnold C. Hanish sold 10,000 shares of the business's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares of the company's stock, valued at $94,750. The trade was a 66.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter B. Cancelmo sold 25,000 shares of the firm's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 105,906 shares of company stock valued at $1,989,705 in the last three months. 10.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings cut Omeros from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 22nd. Cantor Fitzgerald upgraded Omeros from a "neutral" rating to an "overweight" rating and set a $22.00 price objective for the company in a research note on Tuesday, September 22nd. Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Finally, Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.00.

Omeros Price Performance

OMER traded down $0.05 during midday trading on Tuesday, hitting $19.38. 392,591 shares of the company's stock traded hands, compared to its average volume of 1,687,282. The company has a market cap of $1.40 billion, a PE ratio of 15.14 and a beta of 2.60. The stock's fifty day simple moving average is $16.40 and its 200-day simple moving average is $13.11. Omeros Corporation has a one year low of $4.05 and a one year high of $21.24.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, research analysts expect that Omeros Corporation will post -0.37 EPS for the current year.

Omeros Profile

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.